Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vera Therapeutics, Inc. (Nasdaq: VERA) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a late clinical-stage biotechnology company focused on serious immunological diseases, Vera Therapeutics uses SEC filings to report clinical milestones, financing transactions, governance changes, and other material events that can be important for investors analyzing VERA stock.
Current reports on Form 8-K feature prominently in Vera Therapeutics’ filing history. For example, the company has filed 8-Ks describing entry into a Sales Agreement with TD Securities (USA) LLC for potential at-the-market offerings of Class A common stock, the pricing of underwritten public offerings of Class A common stock, and the termination of a prior sales agreement. Other 8-Ks report clinical and regulatory updates, such as ORIGIN Phase 3 trial data for atacicept in immunoglobulin A nephropathy (IgAN), including reductions in proteinuria and safety outcomes, as well as the submission of a Biologics License Application and subsequent communications around FDA review.
Filings also cover corporate governance and compensation. Vera Therapeutics has reported the appointment of new directors, including committee assignments and equity compensation under its non-employee director compensation policy, and changes in executive roles such as the departure of its Chief Legal Officer. Additional disclosures describe inducement equity awards granted under the company’s 2024 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Alongside 8-Ks, investors can access registration statements and prospectus supplements referenced in the filings, which relate to public offerings and shelf registration on Form S-3. These documents outline the terms under which Vera Therapeutics may issue Class A common stock to fund its development programs, including atacicept, VT-109, and MAU868.
On Stock Titan, Vera Therapeutics’ SEC filings are updated in near real time from EDGAR. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as clinical trial disclosures, financing capacity, director and officer changes, and at-the-market sales arrangements. Users can quickly scan which filings relate to clinical data, capital raising, or governance, and then drill down into the full text when more detail is needed.
For those tracking insider and equity-related activity, the filings page complements Forms 4 and other ownership reports by surfacing information on option grants, RSUs, and inducement awards described in 8-Ks. Together, these materials provide a detailed view of how Vera Therapeutics structures incentives and finances its late-stage development efforts in immunology and nephrology.
Vera Therapeutics reports a Schedule 13G filing showing Deep Track-affiliated holders beneficially own 3,921,362 shares of Class A common stock. That holding represents
The filing lists Deep Track Capital, LP and Deep Track Biotechnology Master Fund, Ltd., with shared voting and dispositive power over the 3,921,362 shares, and identifies David Kroin as a control person for the Deep Track entities.
Vera Therapeutics reported that its board appointed Christopher Hite as a Class III director effective March 5, 2026, with his initial term running until the 2027 annual stockholders’ meeting. His compensation follows the company’s non-employee director policy.
On joining the board, Hite received a nonstatutory stock option to purchase 24,937 shares of Class A common stock at an exercise price of $38.85 per share. The option vests monthly over three years, subject to his continued service. He will also receive an annual cash retainer of $45,000, pro-rated for 2026.
Beginning with the 2027 annual meeting, Hite will be eligible each year for an option to buy up to the lesser of 18,000 shares or the number of shares with a grant date fair value not above $400,000, vesting by the next annual meeting or one year from grant. He will sign the company’s standard indemnification agreement, and the company notes there were no special arrangements or related-person transactions tied to his selection.
Vera Therapeutics director receives stock option grant
Vera Therapeutics director Christopher Hite was granted an option to buy 24,937 shares of the company’s stock at an exercise price of $0.00 per share. The option vests monthly over three years, as long as he continues serving the company.
Vera Therapeutics, Inc. director Christopher Hite filed an initial ownership report on Form 3. The data provided lists him as a director of the company and shows no reportable stock transactions or holdings in the transaction section of the filing.
Sofinnova Venture Partners X and related entities now report owning less than 5% of Vera Therapeutics’ Class A common stock. They beneficially own 2,793,987 shares, representing 3.9% of the company, based on 71,355,667 shares outstanding as of February 23, 2026.
The group’s ownership fell below the 5% threshold as of September 30, 2025, primarily because Vera Therapeutics sold additional shares over time. Venture investor Sofinnova characterizes its position as held for investment purposes and may buy more, sell, or distribute shares depending on market conditions and company developments.
Vera Therapeutics is a late clinical-stage biotech focused on serious immunological kidney diseases, led by atacicept for IgA nephropathy (IgAN). In a pivotal Phase 3 trial, atacicept achieved a 46% reduction in proteinuria (UPCR) from baseline and a 42% reduction versus placebo at week 36 (p<0.0001), with a safety profile generally comparable to placebo and fewer serious adverse events.
The company has filed a Biologics License Application for atacicept in IgAN, which received FDA priority review with a PDUFA target action date of July 7, 2026. Vera is also advancing atacicept in other autoimmune kidney diseases through the ORIGIN EXTEND and PIONEER studies, MAU868 for BK virus in kidney transplant recipients, and VT-109, a next‑generation dual BAFF/APRIL inhibitor, all supported by a broad global IP and licensing strategy.
Vera Therapeutics reported a larger full-year 2025 net loss of
The company ended 2025 with
Vera Therapeutics, Inc. Chief Medical Officer Robert Brenner reported a mandated sale of 2,151 shares of Class A Common Stock on February 23, 2026, at a weighted-average price of $41.9839 per share. The sale was an open-market “sell-to-cover” transaction required to satisfy tax withholding obligations from the vesting of restricted stock units under the company’s equity incentive plans and is described as non-discretionary. The trading orders for these tax-related sales occurred over two business days, from February 23 to February 24, 2026. After this sale, Brenner held 50,947 shares of Vera Therapeutics common stock directly.
Vera Therapeutics SVP of Finance Joseph R. Young reported an open-market sale of 3,117 shares of Class A common stock on February 23, 2026, at a weighted-average price of $41.9839 per share. The shares were sold solely to cover tax withholding on vesting RSUs under a mandated sell-to-cover arrangement and were not a discretionary trade. After this transaction, Young directly held 64,722 shares.
Vera Therapeutics, Inc. chief financial officer Sean Grant reported an open‑market sale of 4,949 shares of Class A common stock at a weighted‑average price of $41.9839 per share. According to the disclosure, the transaction was a mandated sell‑to‑cover trade to satisfy tax withholding obligations from vesting restricted stock units rather than a discretionary sale.
After this transaction, Grant directly held 114,181 Vera Therapeutics shares and indirectly held 5,000 additional shares through a trust. The sale occurred as part of trading orders executed over two business days beginning on February 23, 2026 and ending on February 24, 2026.